The effect of aspirin on C-reactive protein as a marker of risk in unstable angina  by Kennon, Simon et al.
The Effect of Aspirin on C-Reactive
Protein as a Marker of Risk in Unstable Angina
Simon Kennon, MB, MRCP,* Christopher P. Price, PHD, FRCPath,† Peter G. Mills, MA, FRCP,*
Kulasegaram Ranjadayalan, MPhil, MRCP,‡ Jackie Cooper, MSc,§ Heather Clarke, PHD, MRCPath,†
Adam D. Timmis, MD, FRCP*
London, United Kingdom
OBJECTIVES This study was designed to assess the interaction between aspirin and C-reactive protein
(CRP) release in unstable angina.
BACKGROUND C-reactive protein release in acute coronary syndromes may be a response to myocardial
necrosis or may reflect the inflammatory process that drives atherogenesis. Aspirin has the
potential to influence CRP release, either by its anti-inflammatory activity or by reducing
myocardial necrosis. The clinical significance of this potential interaction has not previously
been tested.
METHODS We conducted a prospective cohort study of 304 consecutive patients admitted with
non-ST-elevation acute coronary syndromes. Serial blood samples were obtained for CRP
and troponin I assay. End points were cardiac death and nonfatal myocardial infarction during
follow-up for 12 months.
RESULTS A total of 174 patients (57%) were taking aspirin before admission. Patients taking aspirin
had lower troponin I concentrations throughout the sampling period, only 45 (26.0%) having
concentrations .0.1 mg/l compared with 48 (37.8%) patients not taking aspirin (p 5 0.03).
Maximum CRP concentrations were also lower in patients taking aspirin (8.16 mg/l [3.24 to
24.5]) than in patients not taking aspirin (11.3 mg/l [4.15 to 26.1]), although the difference
was not significant. However, there was significant interaction (p 5 0.04) between prior
aspirin therapy and the predictive value of CRP concentrations for death and myocardial
infarction at 12 months. Thus, odds ratios (95% confidence intervals) for events associated
with an increase of 1 standard deviation in maximum CRP concentration were 2.64
(1.22–5.72) in patients not pretreated with aspirin compared with 0.98 (0.60–1.62) in
patients pretreated with aspirin.
CONCLUSIONS The association between CRP and cardiac events in patients with unstable angina is
influenced by pretreatment with aspirin. Modification of the acute-phase inflammatory
responses to myocardial injury is the major mechanism of this interaction. (J Am Coll
Cardiol 2001;37:1266–70) © 2001 by the American College of Cardiology
C-reactive protein (CRP) is an acute-phase reactant in
myocardial infarction and unstable angina. It is an inflam-
matory marker, and peripheral blood concentrations are
variably predictive of cardiac risk, probably because inflam-
mation is related to the extent of myocardial necrosis (1–4).
However, reports that CRP remains predictive of cardiac
risk in troponin-negative individuals suggest that other
mechanisms unrelated to myocardial necrosis may also be
involved (2,3). One possibility is that CRP predicts prog-
nosis because it is a marker of the chronic inflammatory
state that drives atherogenesis and predisposes to plaque
rupture (5–8). This mechanism provides a plausible expla-
nation for the correlation between CRP concentrations and
cardiac risk in apparently healthy individuals (9,10).
Ridker et al. (11) found that in apparently healthy
subjects aspirin reduced event rates only for those with CRP
levels in the highest quartile. This would be consistent with
a direct anti-inflammatory effect, but at doses of aspirin used
for secondary prevention the most important benefit is
inhibition of platelet aggregation, which protects against
ischemic injury by modifying the thrombotic response to
plaque rupture (12–15). At these doses aspirin’s anti-
inflammatory activity is generally considered negligible.
Whatever the relative contributions of direct anti-
inflammatory effects and indirect myocardial protective
effects, aspirin has the potential to reduce CRP release and
interfere with its predictive value for cardiac events. In order
to examine this potential interaction, we have prospectively
analyzed CRP concentrations in an unselected cohort of
patients with non-ST-elevation acute coronary syndromes,
approximately half of whom were taking aspirin, and logged
cardiac events during the first 12 months.
METHODS
Patients. Consecutive patients with non-ST-elevation
acute coronary syndromes were recruited if they fulfilled
criteria for Braunwald class 3B unstable angina (16). Pa-
tients with serum creatine kinase $400 IU/l (upper limit of
reference range: 200 IU/l) or CK-MB $4.0 mg/l without
Q-wave development were diagnosed as non-Q-wave myo-
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cardial infarction. Electrocardiographic changes (ST de-
pression, T-wave inversion) were not required for inclusion,
but patients who developed Q-waves were excluded, as were
patients with myocardial infarction in the previous 21 days.
Other exclusion criteria included percutaneous coronary
intervention in the previous six months and cardiac failure
(New York Heart Association grade 3 or 4). The study
protocol was approved by the East London and the City
Health Authority Research Ethics Committee and all pa-
tients gave informed consent.
Data Collection
CLINICAL DATA. Baseline characteristics including demo-
graphic, clinical and biochemical data as well as details of
the presenting ECG were collected prospectively and stored
electronically. Medication being taken before admission was
documented and all subjects were asked directly regarding
use of aspirin.
BLOOD SAMPLING AND BIOCHEMICAL ANALYSIS. In addi-
tion to samples taken for routine laboratory analysis accord-
ing to hospital protocols, samples were also taken on
admission (before antithrombotic therapy) and at 12, 24 and
48 h after admission for CRP and troponin I assays. After
separation, serum samples were stored at 280°C for analysis
in batches. The troponin I concentrations were measured
using a one-step sandwich immunoassay with magnetic
separation (Bayer Immuno 1 Analyzer: Bayer PLC, New-
bury, United Kingdom). The minimum detection limit was
0.1 mg/l. The coefficient of variation was 3.2% at 2.5 mg/l
and 10% at 0.3 mg/l (manufacturer’s datasheet). As recom-
mended by the manufacturers, the cutoff point used was
0.1 mg/l. C-reactive protein was measured by nephelometry
(N Latex CRP Mono, Dade-Behring, Marburg, Germany).
The lower detection limit was 0.042 mg/l and the coefficient
of variation was 1.5% at 0.3 mg/l, and 1.8% at a concen-
tration of 3 mg/l; the test had been modified to lower the
limit of detection.
FOLLOW-UP. Patients were followed up for 12 months.
Deaths from cardiac causes and nonfatal myocardial infarc-
tion were documented. For patients in whom information
about nonfatal ischemic events was not already available
from outpatient follow-up or readmission to the coronary
care unit, postal questionnaires were used to obtain the
information, backed up by telephone inquiry for non-
responders. In this way, 12-month follow-up data were
obtained in 95.1% of the study group.
STATISTICAL ANALYSIS. C-reactive protein results are pre-
sented as median and interquartile range. Differences in
CRP levels by group were tested using the Mann-Whitney
U test. Troponin-I was analyzed using a cut point of
0.1 mg/l. Associations with events were assessed using
logistic regression models. C-reactive protein was log-
transformed before being entered in the model. Results are
presented as odds ratios (ORs) and 95% confidence inter-
vals. For CRP the OR represents the increased risk associ-
ated with an increase of 1 standard deviation in maximum
blood level, equivalent to a fourfold increase in the untrans-
formed level. An interaction term was fitted in the model to
test whether the CRP association was modified by aspirin
use. Stepwise logistic regression models were fitted and
stratified by aspirin use to determine independent predictors
of death and myocardial infarction within each group.
RESULTS
Discharge diagnosis and outcome. Patient characteristics
are summarized in Table 1. The discharge diagnosis was
non-Q-wave myocardial infarction in 92 patients (30%) and
unstable angina in 212 (70%). Thirty-day follow-up was
obtained in 303 patients (99.7%), of whom one died and
14 had nonfatal myocardial infarction. Twelve-month
follow-up was obtained in 289 patients (95.1%), of whom
seven died and 21 had nonfatal myocardial infarction. All
deaths were attributable to cardiac causes. Event rates in
those who were and were not receiving aspirin therapy prior
to presentation were not significantly different.
Aspirin, troponin I and CRP concentrations (Table 2,
Fig. 1). C-reactive protein collection was complete, but
aspirin data were unavailable in one case and troponin data
in a further three cases. Of the 304 patients, 174 (57%) were
taking aspirin before admission and 129 were not. Patients
taking aspirin had lower troponin I concentrations through-
out the sampling period, only 45 (26.0%) having maximum
concentrations .0.1 mg/l compared with 48 (37.8%) pa-
tients not taking aspirin (p 5 0.03). Patients taking aspirin
also tended to have lower CRP concentrations than patients
not taking aspirin, although the differences were not signif-
Abbreviations and Acronyms
CRP 5 C-reactive protein
OR 5 odds ratio
Table 1. Patient Characteristics: Data Are Numbers (%),
Except for Age and Cholesterol, Which Are Years and mmol/l
(Standard Deviation), Respectively
Variable
Entire
Cohort
(n 5 304)
12-Month
Follow-Up
No Event*
(n 5 261)
Event*
(n 5 28)
p
Value
Age 60.5 (11.2) 60.0 (11.1) 67.5 (11.3) 0.001
Male 227 (74.7) 192 (73.9) 23 (82.1) 0.34
Diabetic 67 (22.0) 53 (20.3) 11 (39.3) 0.03
Hypertensive 135 (44.4) 116 (44.4) 14 (50.0) 0.58
Smoker 97 (31.9) 85 (32.6) 6 (21.4) 0.23
Cholesterol 5.80 (1.17) 5.62 (1.12) 6.11 (1.22) 0.05
Prior aspirin† 174 (57) 152 (58.5) 17 (60.7) 0.82
Troponin I .0.1 mg/l‡ 93 (30.9) 68 (26.4) 19 (67.9) ,0.0001
*Events are death from cardiac causes or nonfatal myocardial infarction. †Patients on
regular treatment with aspirin before presentation. ‡Patients with one or more serum
troponin concentrations .0.01 mg/l.
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icant. Significant correlation was confirmed between CRP
and troponin I concentrations (Fig. 1).
CRP and cardiac events (Tables 3 and 4). Table 3 shows
that at all sampling times, CRP concentrations were higher
in patients who experienced cardiac events than in patients
who did not. However, differences only became significant
after 24 h and were particularly marked in patients not
taking aspirin before admission. Conversely, in patients
taking aspirin, differences never reached statistical signifi-
cance. For an increase of 1 standard deviation in maximum
CRP concentrations, ORs (95% confidence intervals) for
events at 30 days and 12 months were 1.09 (0.52 to 2.31)
and 0.98 (0.60 to 1.62) respectively, rising to 2.65 (1.10 to
6.40) and 2.64 (1.22 to 5.72) in patients not taking aspirin
before admission (Table 4). Thus, in patients taking aspirin,
the ORs showed marked attenuation with lower limits of
confidence well below unity. Significant interaction (p 5
0.04) was confirmed between prior aspirin therapy and the
predictive value of CRP concentrations for cardiac events
during the first 12 months. In a multivariate analysis that
included age, gender and troponin measurements, CRP was
not retained as an independent predictor of events, either for
the entire cohort or the subgroup not taking aspirin.
DISCUSSION
This prospective study of non-ST-elevation acute coronary
syndromes has shown significant association between CRP
concentrations and future cardiac events, particularly in
patients not pretreated with aspirin. The association was
attenuated, however, by pretreatment with aspirin, which
reduced myocardial injury and acute-phase inflammatory
responses.
Aspirin and myocardial injury. The minimal myocardial
injury that may occur in non-ST-elevation coronary syn-
dromes is now recognized as a major predictor of cardiac
events and results in the release of troponins into the
circulation (17–19). Troponin release is almost certainly the
Table 2. Troponin I (mg/l) and C-reactive protein (CRP) (mg/l) Concentrations According to
Prior Aspirin Use: Data for Troponin I Are Number (%) of Patients With Serum Concentration
.0.1 mg/l, and for CRP Are Medians (Interquartile Range)
Sample
Time (h)
Serum
Marker
No Aspirin
(n 5 129)
Prior Aspirin
(n 5 174)
p
Value
0 Troponin I 32 (25.6) 29 (18.0) 0.12
CRP 4.57 (2.36–9.59) 4.25 (1.58–9.56) 0.40
12 Troponin I 42 (36.5) 39 (25.3) 0.05
CRP 4.72 (2.13–11.8) 5.33 (2.05–10.9) 0.31
24 Troponin I 41 (35.0) 39 (25.8) 0.10
CRP 7.69 (3.75–15.9) 5.96 (2.48–16.5) 0.36
48 Troponin I 30 (29.7) 30 (24.8) 0.41
CRP 9.99 (2.47–25.9) 7.38 (3.31–25.6) 0.62
Maximum Troponin I 48 (37.8) 45 (26.0) 0.03
CRP 11.3 (4.15–26.1) 8.16 (3.24–24.5) 0.22
Figure 1. Correlation between peak C-reactive protein (CRP) (mg/l) and troponin I (mg/l) concentrations. Both CRP and troponin concentrations are
plotted on a log scale. Only patients with elevated (.0.1 mg/l) troponin I levels are represented.
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consequence of significant intraluminal thrombosis, with
ischemic injury resulting either from transient coronary
occlusion or from thrombotic embolization into the distal
arterial bed (20). Although the finding that troponin release
is reduced in patients taking aspirin has not previously been
reported, it is a predictable result of antiplatelet activity
modifying the thrombotic response to plaque rupture and
reducing ischemic injury. In this respect it is analagous to
previous studies of acute coronary syndromes in which
pretreatment with aspirin has been associated with less
severe modes of presentation (14,15).
Risk assessment. Our study confirmed the highly signifi-
cant association between troponin positivity and cardiac risk
in non-ST-elevation coronary syndromes, patients with
concentrations .0.1 mg/l comprising 67.9% of the group
with ischemic events in the first 12 months. C-reactive
protein showed a weaker association, similar to that re-
ported by other investigators (1–4). The association be-
tween CRP and cardiac risk is consistent with current
understanding of the inflammatory process acting as a driver
of the atherosclerotic process, and in some (4,21) but not all
studies (22), CRP has been reported to predict death from
cardiac causes independent of troponin status. In this study
an independent association was not demonstrated and the
univariate association only became significant 24 h after
presentation, suggesting that acute-phase inflammatory re-
sponses to myocardial injury were a more important mech-
anism in our patients. The correlation between CRP and
troponin I concentrations lends some weight to this sugges-
tion.
Aspirin, CRP and risk. An important, and hitherto unre-
ported, observation in the present study was the interaction
between prior aspirin therapy and the predictive value of
CRP concentrations for cardiac events during the first 12
months. In patients not pretreated with aspirin each stan-
dard deviation increase in CRP more than doubled the odds
of ischemic events at 30 days and 12 months. In patients
pretreated with aspirin, however, CRP provided no useful
information about cardiac risk. C-reactive protein concen-
trations tended to be lower in these patients, suggesting that
the protection aspirin provided against ischemic myocardial
injury, reflected in reduced troponin release, attenuated
acute-phase inflammatory responses to the point that asso-
ciations between CRP and ischemic events were lost.
Conclusion. The association between CRP and cardiac
events in patients with non-ST-elevation coronary syn-
dromes is influenced by pretreatment with aspirin. The
mechanism of this interaction is not clear, although the
effect of aspirin on troponin release suggests that modifica-
tion of the acute-phase inflammatory responses to myocar-
dial injury may have a role. Regardless of the mechanism,
this study of non-ST-elevation coronary syndromes has
shown that CRP is a significant predictor of cardiac events
only in patients not pretreated with aspirin.
Reprint requests and correspondence: Dr. Simon Kennon, Car-
diology Department, London Chest Hopital, Bonner Rd, London
E2 9JX, United Kingdom. E-mail: srok@dircon.co.uk.
Table 3. C-Reactive Protein Concentrations (mg/l) as a Univariate Predictor of Death or Nonfatal Myocardial Infarction at
30 Days and 12 Months According to Prior Aspirin Treatment: Data Are Median Values (Interquartile Range)
Sample
Time Cohort
30-Day Follow-Up 12-Month Follow-Up
No Event (n 5 288) Event (n 5 15) p Value No Event (n 5 261) Event (n 5 28) p Value
0 All patients 4.34 (1.83–9.59) 6.54 (4.08–9.26) 0.16 4.25 (1.73–9.59) 5.37 (2.91–10.1) 0.38
No aspirin 4.35 (2.17–10.5) 6.54 (4.52–8.59) 0.31 4.24 (1.95–10.6) 5.96 (4.12–8.71) 0.23
Prior aspirin 4.25 (1.58–9.39) 7.09 (3.29–13.1) 0.38 4.36 (1.58–9.11) 3.99 (1.23–13.4) 0.91
12 All patients 4.86 (2.09–11.8) 7.68 (2.88–10.4) 0.52 4.86 (2.02–11.8) 7.41 (2.4–11.7) 0.81
No aspirin 4.42 (2.11–12.1) 7.9 (6.22–10.05) 0.51 4.37 (1.85–13.4) 7.90 (5.03–10.40) 0.41
Prior aspirin 5.34 (2.05–10.9) 4.05 (1.45–27.4) 0.84 5.34 (2.05–10.6) 3.89 (1.45–13.10) 0.73
24 All patients 6.36 (2.8–15.2) 20.2 (7.12–34.2) 0.02 6.15 (2.8–14.2) 15.7 (4.0–30.0) 0.06
No aspirin 7.02 (3.38–14.4) 21.7 (10.3–34.2) 0.02 6.76 (2.93–13.60) 24.25 (10.30–34.20) 0.007
Prior aspirin 5.96 (2.48–15.4) 12.4 (4.0–42.4) 0.37 5.96 (2.62–15.10) 5.16 (2.11–27.65) 0.84
48 All patients 8.5 (3.04–24.95) 40.4 (7.03–89.4) 0.01 8.3 (2.72–24.25) 39.3 (6.36–56.8) 0.004
No aspirin 9.66 (2.44–24.7) 56.8 (30.4–98.2) 0.02 9.36 (2.41–24.6) 47.9 (18.09–77.5) 0.009
Prior aspirin 7.34 (3.31–25.2) 23.4 (7.03–50.4) 0.17 7.38 (3.31–19.7) 23.4 (6.36–50.4) 0.13
Maximum All patients 9.31 (3.43–24.6) 23.4 (7.03–56.8) 0.08 9.3 (3.44–23.7) 17.6 (4.24–56.65) 0.15
No aspirin 10.4 (3.83–24.6) 32.3 (11–77.5) 0.03 10.9 (3.71–24.6) 34.2 (10.3–63.9) 0.01
Prior aspirin 8.52 (3.31–23.8) 7.03 (2.09–50.4) 0.95 8.54 (3.43–19.7) 6.36 (2.4–46.1) 0.78
Table 4. Odds Ratios for Association of Maximum C-Reactive
Protein (CRP) Concentrations With 30-Day and 12-Month
Event-Free Survival According to Prior Aspirin Treatment
Odds Ratio
(95% Confidence Interval)
p Value
for Interaction
30-day follow-up
No aspirin 2.65 (1.10–6.40)
0.13
Prior aspirin 1.09 (0.52–2.31)
12-month follow-up
No aspirin 2.64 (1.22–5.72)
0.04
Prior aspirin 0.98 (0.60–1.62)
Odds ratios for a 1 standard deviation increase in maximum CRP are from a logistic
regression model with an interaction term to test if the association between CRP and
event rates differs according to prior aspirin treatment.
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